Company · CIK 1018735
NYMOX PHARMACEUTICAL CORP
| CIK | 1018735 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2835 — In Vitro & In Vivo Diagnostic Substances |
| Business address | Quebec, Canada |
| Listed | NYMXF (OTC) |
| First annual or quarterly report | 1998-05-08 |
Offerings
5 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-263932 | 2022-03-29 | 2022-04-12 | 2 | |
| 333-261571 | 2021-12-09 | 2022-03-22 | 3 | |
| 333-256024 | 2021-05-12 | 2021-05-20 | 2 | |
| 333-237564 | 2020-04-03 | 2020-08-14 | 5 | |
| 333-205659 | 2015-07-14 | 2016-02-09 | 3 |
Filings
15| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2022-04-12 | EFFECTDeclared effective | 333-263932 | 9999999995-22-000946 |
| 2022-03-29 | F-3Shelf registered | 333-263932 | 0001640334-22-000599 |
| 2022-03-22 | 424B5Shelf takedown | 333-261571 | 0001640334-22-000556 |
| 2022-01-28 | EFFECTDeclared effective | 333-261571 | 9999999995-22-000267 |
| 2021-12-09 | F-3Shelf registered | 333-261571 | 0001640334-21-003105 |
| 2021-05-20 | EFFECTDeclared effective | 333-256024 | 9999999995-21-002045 |
| 2021-05-12 | F-3Shelf registered | 333-256024 | 0001640334-21-001119 |
| 2020-08-14 | 424B5Shelf takedown | 333-237564 | 0001640334-20-002108 |
| 2020-08-14 | 424B5Shelf takedown | 333-237564 | 0001640334-20-002102 |
| 2020-07-17 | 424B5Shelf takedown | 333-237564 | 0001640334-20-001812 |
| 2020-05-12 | EFFECTDeclared effective | 333-237564 | 9999999995-20-001125 |
| 2020-04-03 | F-3Shelf registered | 333-237564 | 0001640334-20-000720 |
| 2016-02-09 | 424B5Shelf takedown | 333-205659 | 0001176256-16-000420 |
| 2015-08-04 | EFFECTDeclared effective | 333-205659 | 9999999995-15-002173 |
| 2015-07-14 | F-3Shelf registered | 333-205659 | 0001176256-15-000245 |